Special aspects of remodeling of the left ventricle in hypertensive disease
https://doi.org/10.21886/2219-8075-2017-8-4-14-22
Abstract
Arterial hypertension remains the leading cause of death in the world and one of the global problems of the world healthcare.
Left ventricular hypertrophy is a frequent complication of arterial hypertension, which in turn is a powerful independent predictor of morbidity and mortality. With a prolonged course of the disease, there are several models of remodeling the left ventricle. In this connection, this literature review presents diff erent points of view on the problem, as well as directions for further fundamental and practical research.
About the Authors
Mariya V. OzherelevaRussian Federation
Moscow
Artem G. Ovchinnikov
Russian Federation
Ph.D.
Moscow
References
1. Campanini B. Th e World Health Report: Reducing Risk, Promoting Healthy Life. - Geneva, World Health Organization; 2002.
2. Kaplan N, Opie L. Controversies in hypertension. Lancet. 2006;367:168–76. DOI: 10.1016/S0140-6736(06)67965-8
3. Schmieder R, Martus P, Klingbeil A. Reversal of left ventricular hypdertrophy in essential hypertension: metaanalysis of randomized studies. JAMA. 1996;275:1507—13.
4. Lavie C., Milani R., Ventura H., Messerli F. Left ventricular geometry and mortality in patients >70 years of age with normal ejection fraction. Am J Cardiol. 2006;98:1396–9. DOI: 10.1016/j.amjcard.2006.06.037
5. Frohlich E, Apstein C, Chobanian A, Devereux RB, Dustan HP, Dzau V, et al. Th e heart in hypertension. N Engl J Med. 1992;327:998—1008. DOI: 10.1056/NEJM199210013271406
6. Meerson F. Th e failing heart. In: Katz A., ed. Adaptation and de-adaptation. New York: Raven Press, 1983.
7. Aurigemma G., Silver K., Priest M., Gaasch W. Geometric changesallow normal ejection fraction despite depressed myocardial shortening in hypertensive left ventricular hypertrophy. J Am Coll Cardiol .1995;26: 195—202.
8. Kozàkovà M., de Simone G., Morizzo C., Palombo C. Coronary vasodilator capacity and hypertension-induced increase in left ventricular mass. Hypertension. 2003;41:224.
9. Schwartzenberg S, Redfi eld MM, From AM, Sorajja P, Nishimura RA, Borlaug BA. Eff ects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol. 2012;59:442–51. doi: 10.1016/j.jacc.2011.09.062
10. Levy D, Garrison R, Savage D, Kannel WB, Castelli WP.. Left ventricular mass and incidence of coronary heart disease in an elderly cohort: the Framingham Heart Study. Ann Intern Med. 1989;110:101—7.
11. Ageev FT, Ovchinnikov AG. Left ventricular fi lling pressure: pathogenesis and ultrasonic assessment. Russian Heart Failure Journal. 2012;13(5):287-309. (in Russ.) DOI: 10.18087/rhfj .2012.5.1748
12. Cory C., Grange R., Houston M. Role of sarcoplasmic reticulum in loss of load sensitive relaxation in pressure overload cardiac hypertrophy. Am J Physiol. 1994;266:H68—H78.
13. Arai M., Matsui H., Periasamy M. Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure. Circ Res. 1994;74:555—64.
14. De la Bastie D, Levitsky D, Rappaport L, et al. Function of the sarcoplasmic reticulum and expression of its Са2+ ATPase gene in pressure-overloaded cardiac hypertrophy in the rat. Circ Res. 1990;66:554—64.
15. Weber K, Brilla C, Janicki J. Myocardial fi brosis: functional signifi cance and regulatory factors. Cardiovasc Res. 1993;27:341—8.
16. Palmieri V, Bella JN, Arnett DK, Liu JE, Oberman A, Schuck MY, et al. Eff ect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) study. Circulation. 2001;103:102—7.
17. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000;52:11—34.
18. Brilla C, Maisch B. Regulation of the structural remodeling of the myocardium: from hypertrophy to heart failure. Eur Heart J. 1994;15 (suppl D):45—52.
19. Kawano H, Do Y, Kawano Y, Starnes V, Barr M, et al. Angiotensin II has multiple profi brotic eff ects in human cardiac fi broblast. Circulation. 2000;101:1130—7.
20. Kahan T. Th e importance of left ventricular hypertrophy in human hypertension. J Hypertens. 1998;16(Suppl):23.
21. Verdecchia P, Shillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I et al. Prognostic signifi cance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97:48.
22. Kent R, McDermott PJ. Passive load and angiotensin II evoke diff erential responses of gene expression and protein synthesis in cardi[ac myocytes. Cir Res. 1996;78:829—38.
23. Redfi eld MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheff er RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194—202.
24. Pfeff er MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, et al. Eff ect of captopril on mortality and morbidity in patients with left ventricular dysfunction aft er myocardial infarction. Results of the survival and ventricular enlargement trial. Th e SAVE Investigators. N Engl J Med. 1992;327: 669–77. DOI: 10.1056/NEJM199209033271001
25. Rame JE, Ramilo M, Spencer N, Blewett C, Mehta SK, et al. Development of a depressed left ventricular ejection fraction in patients with left ventricular hypertrophy and a normal ejection fraction. Am J Cardiol. 2004;93:234—7.
26. Sehgal S., Drazner M. Left ventricular geometry: does shape matter? Am Heart J. 2007;153:153–5. DOI: 10.1016/j.ahj.2006.10.026
27. Ofi li E., Cohen J., St Vrain J., et al. Eff ect of treatment of isolated systolic hypertension on left ventricular mass. JAMA. 1998;279:778. doi:10.1001/jama.279.10.778
Review
For citations:
Ozhereleva M.V., Ovchinnikov A.G. Special aspects of remodeling of the left ventricle in hypertensive disease. Medical Herald of the South of Russia. 2017;8(4):14-22. (In Russ.) https://doi.org/10.21886/2219-8075-2017-8-4-14-22